The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
β-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial
Open accessAbstract
In patients with type 1 diabetes, measurement of connecting peptide (C-peptide), cosecreted with insulin from the islets of Langerhans, permits estimation of remaining β-cell secretion of insulin. In this retrospective analysis to distinguish the incremental benefits of residual β-cell activity in type 1 diabetes, stimulated (90 min following ingestion of a mixed meal) C-peptide levels at entry in the Diabetes Control and Complications Trial (DCCT) were related to measures of diabetic retinopathy and nephropathy and to incidents of severe hypoglycemia. Based on the analytical sensitivity of the assay (0.03 nmol/l) and study entry criteria, the DCCT subjects were divided into four groups of stimulated C-peptide responses: ≤0.03, 0.04–0.20, 0.21–0.50 nmol/l at entry, and 0.21–0.50 nmol/l at entry and at least 1 year later (sustained C-peptide secretion). Uniformly in the intensive and partially in the conventional DCCT treatment groups, any C-peptide secretion, but especially at higher and sustained levels of stimulated C-peptide, was associated with reduced incidences of retinopathy (both a single three-step change and a repeated three-step change on the Early Treatment of Diabetic Retinopathy Study [ETDRS] scale at the next 6 month visit) and nephropathy (both albuminuria >40 mg/24 h once and repeated at the next annual visit). There were also differences in severe hypoglycemia across C-peptide levels in both treatment groups. In the intensively treated cohort there were essentially identical prevalences of severe hypoglycemia (∼65% of participants) in the first three groups; however, those subjects with mixed-meal stimulated C-peptide level >0.20 nmol/l for at least baseline and the first annual visit in the DCCT experienced a reduced prevalence of ∼30%. Therefore, even modest levels of β-cell activity at entry in the DCCT were associated with reduced incidences of retinopathy and nephropathy. Also, continuing C-peptide (insulin) secretion is important in avoiding hypoglycemia (the major complication of intensive diabetic therapy).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although this endogenous secretion is typically low, maintenance is important since it is associated with less retinopathy and less severe hypoglycaemia at later stages of the disease.86”
From Type 1 diabetes (2014) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“natural history studies, intervention trials, and transplantation studies consistently show that higher Cpeptide responses to a mixed meal are associated with improved glycaemic control, fewer hypoglycaemic episodes, and reduced longterm complications.[55][56][57]”
From The future of type 1 diabetes therapy (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This finding is noteworthy because in the Diabetes Control and Complications Trial68,69 persistent C-peptide secretion was associated with reduced development of retinopathy, nephropathy, and hypoglycaemia.”
From Type 1 diabetes (2018) · cites this paper as [69]
In the citing paper
“In addition, we analysed two other thresholds: UCPCR≥0.03 nmol/mmol and ≥0.2nmol/mmol, which are equivalent to serum C peptide of 30 pmol/L (a common historical limit of detection(3; 11; 12)) and 200 pmol/L (a clinically defined level associated with reduced microvascular complications and hypoglycaemia(13)).”
From Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors (2015) · cites this paper as [11]
In the citing paper
“The strongest evidence to date, however, finds that while higher and sustained levels of C-peptide are most beneficial, even modest levels of β-cell function in some with long-term disease are associated with lower rates of hypoglycemia and lower incidence of retinopathy and nephropathy (9,11).”
From Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay (2012) · cites this paper as [11]
In the citing paper
“The strongest evidence to date, however, finds that while higher and sustained levels of C-peptide are most beneficial, even modest levels of β-cell function in some with long-term disease are associated with lower rates of hypoglycemia and lower incidence of retinopathy and nephropathy (9,11).”
From Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay (2012) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,602
The design and analysis of cohort studies
Breslow, N. E., & Day, N. E. (1987) · International Agency for Research on Cancer eBooks · Cited by 1,312
The Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-7-199804010-00001 · Cited by 546
The DCCT Research Group (1986) · Diabetes · doi:10.2337/diabetes.35.5.530 · Cited by 466
(1995) · Archives of Ophthalmology · doi:10.1001/archopht.1995.01100010038019 · Cited by 325
Hypoglycemia: The Limiting Factor in the Management of IDDM
Cryer, P. E. (1994) · Diabetes · doi:10.2337/diab.43.11.1378 · Cited by 307
THE DCCT RESEARCH GROUP (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-1-30 · Cited by 215
Cited by
Sorted by citations
Items 601–697 of 697
Warncke, K., Eckert, A. J., Bonifacio, E. E., Achenbach, P., Kordonouri, O., Meißner, T., Ohlenschläger, U., Bonfig, W., Ziegler, A., & Holl, R. W. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102208 · Cited by 1
Defining Outcomes for β-Cell Replacement Therapy
Rickels, M. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_65 · Cited by 1
Barmpagianni, A., Karamanakos, G., Anastasiou, I. A., Kountouri, A., Lambadiari, V., & Liatis, S. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108946 · Cited by 1
Tertiärprävention des Typ-1-Diabetes
Link, S., & Schloot, N. C. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0729-5 · Cited by 1
Faustman, D. L., & Davis, M. (2015) · InTech eBooks · doi:10.5772/61234 · Cited by 1
Cryer, P. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00034-4 · Cited by 1
Chen, Y., Chen, Q., Zhang, Y.-X., Liu, F., Yang, H., Wu, S.-N., & Wei, H. (2018) · PubMed Central · doi:10.7499/j.issn.1008-8830.2018.12.008 · Cited by 1
Glucagon stimulation test as a possible predictor of residual β‐cell function
Yoshida, K., Urakami, T., & Morioka, I. (2021) · Pediatrics International · doi:10.1111/ped.14462 · Cited by 2
The TUDID Study – Background and Design of a Prospective Cohort
Jaghutriz, B. A., Wagner, R. J., Kullmann, S., Fritsche, L., Eckstein, S. S., Dannecker, C., Willmann, C., Randrianarisoa, E., Lehn‐Stefan, A., Hieronimus, A., et al. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1221-9618 · Cited by 1
Precision Exercise and Physical Activity for Diabetes
Boulé, N. G., & Yardley, J. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_13 · Cited by 1
Preserved C-peptide is common and associated with higher time in range in Chinese type 1 diabetes
Liu, W. Y., Fang, Y., Cai, X., Zhu, Y. M., Zhang, M., Han, X., Li, J., Yin, S., Cai, D., Chen, J., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1335913 · Cited by 2
Risk factors for retinopathy in type 1 diabetes
Hietala, K. (2013) · Työväentutkimus Vuosikirja · Cited by 1
Type 1 Diabetes: Clinical and Experimental
Chiarelli, F., & Marcovecchio, L. (2010) · Yearbook of pediatric endocrinology · doi:10.1159/000320658 · Cited by 1
Diabetes vaccines: review of the clinical evidence
Ludvigsson, J. (2011) · Clinical Investigation · doi:10.4155/cli.10.18 · Cited by 1
Is It Time to Take a Different Approach to Screening People at High Risk for Type 1 Diabetes?
Boyko, E. J., & Palmer, J. P. (2009) · Diabetes Care · doi:10.2337/dc09-0388 · Cited by 1
Insel(zell)transplantation bei Typ-1-Diabetes-mellitus
Schmid, J., Ludwig, B., & Brendel, M. D. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0731-y · Cited by 1
Chen, M. Z., & Andrews, R. C. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch26 · Cited by 1
Yang, Y., & Sohn, T. S. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0028 · Cited by 1
Prevention of Type 1 Diabetes Mellitus
Pozzilli, P., & Guglielmi, C. (2015) · Springer eBooks · doi:10.1007/978-3-319-20797-1_49-1 · Cited by 1
Impact of Islet Cell Transplantation on Diabetic Retinopathy in Type 1 Diabetes
Begg, I. S., Warnock, G. L., & Thompson, D. M. (2011) · Springer eBooks · doi:10.1007/978-1-60761-150-9_20 · Cited by 1
Hypoglycemia and other complications of insulin therapy
Amiel, S. A. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch53
Amiel, S. A. (2013) · Wiley eBooks · doi:10.1002/9781118695432.ch7
Insulin Therapy and Hypoglycemia - Present and Future
Cernea, S., Nagar, R., Bitton, G., & Raz, I. (2011) · InTech eBooks · doi:10.5772/24844
Glomerulopathy in normoalbuminuric adolescents with type 1 diabetes
Torbjörnsdotter, T. (2005)
TRANSLATIONAL MEDICINE AND ITS IMPACT ON DIABETES DRUG DEVELOPMENT
Calle, R. A., & Taylor, A. E. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511976087.004
Diabetes Technology and Treatment in the Pediatric Age Group
Wherrett, D., Bundy, B., Becker, D. J., Dimeglio, L., Gitelman, S., Goland, R., Gottlieb, P. A., Greenbaum, C., Herold, K., Marks, J., et al. (2012) · Diabetes Technology & Therapeutics · doi:10.1111/j.1742-1241.2011.02857.x · Cited by 51
Diabetes mellitus in Adults - Aspects of Incidence, Autoimmunity and C-peptide
Thunander, M. (2011) · Lund University Publications (Lund University)
横田, 繁., & ヨコタ, シ. (2013) · SOKENDAI (Graduate University for Advanced Studies)
Insel(zell)-Transplantationen bei Typ-1-Diabetes-Patienten
Brendel, M. D., Ludwig, B., Eckhard, M., & Bretzel, R. G. (2010) · Der Diabetologe · doi:10.1007/s11428-010-0561-3
Periodontal microorganisms, obesity, chronic inflammation, and type 1 diabetes
Nahhas, G. J. (2014) · Scholar Commons (University of South Carolina)
Typ-1-Diabetes und Leistungssport
Strobel, S., Gehr, B., Landgraf, R., & Thurm, U. (2015) · Der Diabetologe · doi:10.1007/s11428-015-0029-6
Characteristics of GADA in Type 1 Diabetes following Immunomodulation with GAD65
Chéramy, M. (2012) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Greenbaum, C. J. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0017-8
Mechanisms of transcriptional regulation in the maintenance of β cell function
Maganti, A. V. (2015) · IUScholarWorks (Indiana University) · doi:10.7912/c2b88b
Maurice, E., & Lemineur, R. (1977) · PubMed
Diabetesintervention mit Atorvastatin (DIATOR)
Martin, S. (2005) · Der Diabetologe · doi:10.1007/s11428-005-0001-y
Dubois‐Laforgue, D. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30099-2
Autoimmune Diseases in Childhood
Karmazsin, L., Péter, F., & Szombathy, G. (2024) · Frontiers research topics · doi:10.3389/978-2-8325-5731-0
Ludvigsson, J. (2016) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2016.03.00063
Insulin and Immunotherapy in Children and Adolescents with Type 1 Diabetes
Ludvigsson, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-40242-0_3
Supporting patients with type 1 diabetes
Phillips, A. (2017) · Practice Nursing · doi:10.12968/pnur.2017.28.1.28
Release from Human Erythrocytes.
Richards, J. P., Stephenson, A. H., Ellsworth, M. L., & Sprague, R. S. (2013)
Examining the barriers and benefits to exercise in adults with newly diagnosed type 1 diabetes
Kennedy, A. (2017) · University of Birmingham Institutional Research Archive (University of Birmingham)
Scott, S. N., Riddell, M. C., & Yardley, J. E. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-030-33376-8_25
Transplantation und künstliches Pankreas
Ludwig, B., & Wolf, E. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00670-3
Latent autoimmune diabetes in adults (LADA)
Pop, O. (2020) · Medic ro · doi:10.26416/med.135.3.2020.3238
Kahkoska, A. R. (2020) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/pmkd-k264
Caviglia, G. P., Rosso, C., Armandi, A., Ribaldone, D. G., Pellicano, R., & Bugianesi, E. (2021) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.20.02710-x
Lord, S. M., & Greenbaum, C. J. (2021) · Kompass Autoimmun · doi:10.1159/000516244
Autoimmunerkrankung Typ-1-Diabetes
Scherm, M. G., & Daniel, C. (2021) · Diabetes aktuell · doi:10.1055/a-1452-1412
GAD65 An Immunomodulator in Type 1 Diabetes
Axelsson, S. (2012) · DiVA (Linkoping University)
El ordenamiento juridico informativo en España
Guanter, J. M. D. (1990) · Situación: revista de coyuntura económica
Associação entre o gene da Butrilcolinesterase e Diabete Melito Tipo 1
Fernandes, A. B. (2010) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Análise do polimorfismo HLA/DR-DQ em Angolanos portadores de Diabetes Mellitus tipo I
Ramos, N. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Hamilton, M. (2013) · CommonKnowledge Research Repository (Pacific University Oregon)
Future Drug Treatment for Type 1 Diabetes
Larsson, H. E., Delli, A. J., Ivarsson, S. A., & Lernmark, Å. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch59
Diabetes Technology and Treatment in the Paediatric Age Group
Shalitin, S., & Chase, H. P. (2012) · Wiley eBooks · doi:10.1002/9781118321508.ch11
Current literature in diabetes
John Wiley & Sons, L. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.466
Stammzelltherapie bei Typ-1-Diabetes
Ludwig, B. (2022) · Diabetes aktuell · doi:10.1055/a-1834-3188
Pankreasinseltransplantation – State of the Art
Ludwig, B., & Lehmann, R. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00933-1
CLOuDs Disperse — Top-Notch Glucose Control and Residual C-Peptide Secretion
Bolinder, J. (2022) · New England Journal of Medicine · doi:10.1056/nejme2209740
Cimbek, E. A., BEKFİLAVİOĞLU, S., & Karagüzel, G. (2022) · Turkish Journal of Diabetes and Obesity · doi:10.25048/tudod.1170939
Managing latent autoimmune disease in adults
Morris, D. (2023) · Independent Nurse · doi:10.12968/indn.2023.1.18
Circadian rhythm of glycemic control in patients with mellitus diabetes
Vásquez-Muñoz, M. (2023) · doi:10.48035/tesis/2454/44695
Jecht, M. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01051-2
A new strategy for the fight against type 1 diabetes mellitus
Comoglio, M. (2023) · The Journal of AMD · doi:10.36171/jamd23.26.3.6
Iqbal, A., Chow, E., Jones, T. W., & Heller, S. R. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch40
Physical Activities and Diabetes
Cockcroft, E., & Andrews, R. C. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch28
Predictive biomarkers of rapidly developing insulin deficiency in children with type 1 diabetes
Lundkvist, P., Grönberg, A., Carlsson, P., Ludvigsson, J., & Espes, D. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003924
Diabetes Technology and Therapy in the Pediatric Age Group
Maahs, D. M., Prahalad, P., Schweiger, D. Š., & Shalitin, S. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.2508
Stars and Rising Stars in Pediatric Endocrinology: 2022
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4686-4
Januszewski, A. S., Grzelka‐Woźniak, A., Flotyńska, J., Jenkins, A. J., Zozulińska‐Ziółkiewicz, D., & Uruska, A. A. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108828
Müller‐Wieland, D., Miszon, M., Dunstheimer, D., Forst, T. M., Kapellen, T. M., Schnell, O., & Kellerer, M. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2377-7108 · Cited by 1
Do GLP-1 receptor agonists have a place in the treatment of people with type 1 diabetes?
Dejgaard, T. F., Frandsen, C. S., Holst, J. J., & Madsbad, S. (2024) · Medical Research Archives · doi:10.18103/mra.v12i12.6110
Numasawa, K., Shiga, K., Kitao, M., Konno, H., Nishiyama, K., Ohsugi, K., Ebina, K., Kikuchi, N., & Ito, S. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0517
Dieta chetogenica e diabete mellito di tipo 2. Come gestire la terapia diabetologica?
Zanni, E., Boni, S., Caprio, M., Rochira, V., & Greco, C. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01719-5
Roshandel, D., Chen, Z., Canty, A. J., Bull, S. B., Natarajan, R., & Paterson, A. D. (2020) · Figshare · doi:10.6084/m9.figshare.12085212
Koška, J., Nuyujukian, D. S., Bahn, G., Zhou, J. J., & Reaven, P. D. (2021) · Figshare · doi:10.6084/m9.figshare.17149648
Ramos, E. F., & Brennan, D. C. (2026) · Kidney News · doi:10.62716/kn.002112025
Guo, H., Lu, Y., Li, J., Wu, M., Xiao, Y., Wan, Y., Shi, B., & Lu, P. (2026) · Current Eye Research · doi:10.1080/02713683.2026.2612760
Nguyen, L. T., Nguyen, H. T., Nguyen, K. T., Hoang, V. H., Phan, T. T. K., Nguyen, A. T. P., Ha, T. A., Liang, R.-Y., Lin, P., Tsai, Y.-C., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8189178/v1
High-dose vitamin D therapy and prolonged partial remission of type 1 diabetes — a case report
Garcia, A. C.-G., Cossen, K., & Nwosu, B. U. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1788049
Yanovskaya, E. A., & Яновская, М. Е. (2026) · FOCUS Endocrinology · doi:10.62751/2713-0177-2026-7-1-05
Vitamin D Is a Key Disease-Modifying Therapy for Type 1 Diabetes
Nwosu, B. U. (2026) · Contemporary Endocrinology · doi:10.1007/978-3-032-17036-1_4
Hu, X., Liu, W. T., Fang, Y., Zhu, Y., Zhang, M., Gong, S., Wang, X., Lin, C., Liu, G., Yang, X., et al. (2026) · Health Data Science · doi:10.34133/hds.0298
Relevance of Quantitative Measures of Beta-Cell Function in Clinical Practice
Galderisi, A., Dayan, C. M., Colhoun, H. M., & Gregory, J. M. (2026) · Hormone Research in Paediatrics · doi:10.1159/000552501
El-Reshaid, K., & Al-Bader, A. (2026) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2026.162006
Eye Health Among Islet Cell Transplant Recipients With Long-duration Type 1 Diabetes
Kwon, H. J., McAuley, S. A., MacIsaac, R. J., Kay, T., & Ward, G. M. (2026) · Transplantation Direct · doi:10.1097/txd.0000000000001960
Spotlight on the Pathology of Type 1 Diabetes
Ling, E. M., Lemos, J. R. N., Quesada‐Masachs, E., Hirani, K., & von Herrath, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00016-0
Kang, J., Huang, Q., Jiang, Y., & Chen, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1891725
Caballero-Corbalán, J., Lundkvist, P., Espes, D., & Carlsson, P. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71204
Dave, C. V., Lloyd, K., Nyandege, A. N., Roy, J., López‐Díez, R., Radovick, S., & Strom, B. L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71279
Nehme, M., Samuna, I. B., Messier, V., Dawe, P., Brazeau, A., & Taleb, N. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109417
Lone, S., Badal, D., Mukherjee, S., Bhadada, S. K., Bhat, S., Garg, P., Basak, P., Banerjee, S., Taneja, S., Subin, S., et al. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113612
Kathirvel, G., Dayal, D., Naresh, S., Kumar, M., & Attri, S. V. (2026) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2026-0474
Metadata
- Authors
- Steffes, M. W., Sibley, S., Jackson, M., & Thomas, W.
- Affiliations
- University of Minnesota (US)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-03-01
- Volume
- 26
- Issue
- 3
- Pages
- 832-836
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1988519907
- Cited by
- 695
- References
- 25
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 30 · 2023: 34 · 2022: 39 · 2021: 49 · 2020: 38 · 2019: 29 · 2018: 31 · 2017: 32 · 2016: 30 · 2015: 44 · 2014: 32 · 2013: 53 · 2012: 37
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (M01RR000400, M01-RR00400)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, residual beta-cell function, C-peptide, diabetic retinopathy, diabetic nephropathy, albuminuria, severe hypoglycemia, intensive insulin therapy, diabetes complications, Diabetes Control and Complications Trial
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Diabetic Retinopathy, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Islets of Langerhans, Male, Retrospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
